Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Innovation & Technologie Angebot

A French technology transfer office offers a method to determine the risk level to induce the torsade de pointes.

Country of Origin: France
Reference Number: TOFR20181025002
Publication Date: 13 November 2018

Summary

The French TTO (Technology Transfer Office) is acting on behalf of major hospital and research group of the Paris region that has designed and patented a new a method to determine the risk level to induce the torsade de pointes.  The French public research centre is looking for interested medtech corporates or biotechnology companies for a technical cooperation or a license agreement.

Description

A French Technology Transfer Office (TTO) is acting on behalf a major hospital and research group in the Paris region that has designed a method to determine the risk level to induce the torsade de pointes.

* Market challenges :
Torsades de pointes (ventricular rhythm disorder) induced by drugs are a public health problem. The mechanism of action of this adverse effect is the inhibition of a potassium channel involved in the ventricular repolarization called Ikr. Electrocardiographically, this adverse effect is notably responsible for a prolongation of the QT interval.

* State of the art :
QT measurement is the marker currently recommended to estimate the degree of inhibition of Ikr. However, it is a very imperfect parameter for the evaluation of drugs in humans and for determining the risk of cardiac disorders in a patient following the use of a drug having such adverse effects.

* Proposed technology :
The developed method allows to determine, after a simple electrocardiogram measurement, whether a patient is likely to present a torsade de pointes event after the administration of a drug. The information analyzed by an algorithm allows to determine a patient risk of occurrence of a cardiac repolarization disorder induced by a substance. It also provides data on the torsadogenic potential of pharmaceutical preparations or substances during their evaluation in humans.

*Partnership :
The partner sought could be a company interested in :
- a license agreement as the TTO is ready to negociate directly the patents rights for specific applications, or,
- a technical cooperation agreement if the industrial application can benefit directly from the actual technology to develop an industrial prototype.


*Keywords :
#Cardiology
#Torsades de pointes
#QT
#Algorithm
Image

Advantages and Innovations

The advantages of this new technology are:

- It is very accurate;
- It provides data during drugs evaluation;
- It can be integrated into existing devices.

Stage Of Development

Under development/lab tested

Stage Of Development Comment

The efficiency of technology has been demonstrated in a prospective clinical study but remains as a pre-proof of concept. Technical developments have to be done in order to to integrate the algorithm.

Requested partner

The TTO is looking for an industrial partner for prototyping and commercializing the technology.

The partner sought could be medtech corporates or biotechnology companies interested in :

- a licencing agreement as the TTO is ready to negotiate directly the patents rights for specific applications;

- a technical cooperation. The eventual partner should have a clear industrial application in mind and a strong technical background to co-develop a prototype.

Cooperation offer ist closed for requests